latest IPO in India Influx Healthtech Ltd is generating significant interest. With its debut on the NSE-SME platform in June 2025, the company’s SME-sized public issue offers investors a unique window into the burgeoning healthtech CDMO sector.

Company Overview

Influx Healthtech Ltd, founded in 2020 and headquartered in Mumbai, operates as a Contract Development & Manufacturing Organization (CDMO). It manufactures nutraceuticals, cosmetics, ayurvedic, veterinary, and homecare products across certified facilities in Thane covering ~36,000 sq ft.

IPO Timeline

• Open Date: 18 June 2025
• Close Date: 20 June 2025
• Basis of Allotment: 23 June 2025
• Refunds & Demat Credit: 24 June 2025
• Listing Date: 25 June 2025

Price Band

The IPO offers a price band of ₹91 to ₹96 per equity share (face value ₹10), representing 9.1–9.6× FV.

Lot Size

Each lot comprises 1,200 shares, with a minimum investment of ₹1,09,200–₹1,15,200 depending on the final price band.

Key Dates

• UPI Mandate Deadline: 20 June 2025, 5 PM
• Anchor Investor Lock-in: 50% for 30 days, balance 90 days post allotment

Financials

• FY25: Revenue ₹105 mn, PAT ₹13.4 mn, EBITDA ₹20.7 mn
• FY24: Revenue ₹100 mn, PAT ₹11.1 mn, EBITDA ₹17.0 mn

Strengths

• Certified facilities (GMP, HACCP, ISO, Halal, FDA)
• Diverse product range: nutraceuticals, veterinary, ayurvedic, more
• Led by experienced pharma professionals

Risks

• SME IPOs have higher volatility
• Short performance history makes valuation sensitive
• Highly competitive and regulated CDMO space

IPO Anchor Investors Details

Investor Category	Shares Allocated	Percentage
Anchor Investors	1,736,400	28.46%
QIBs	1,159,200	19.00%
NIIs	870,000	14.26%
RIIs	2,029,200	33.26%

IPO Promoter Holding Details

Shareholder Group	Pre‑Issue Holding	Post‑Issue Holding
Promoter Group	99.85%	73.53%
Public Group	0.15%	26.47%

IPO Grey Market Premium (GMP)

Date	IPO GMP (₹)	GMP (%)
Mid‑June 2025	₹31	32.3%
Around issue time	₹21–₹22	~22%

IPO Subscription Status

Subscription data was pending at announcement. However, retail and institutional interest is expected to be strong given GMP and SME sentiment.

Final Thoughts

Influx Healthtech stands out as a promising SME IPO in the healthtech CDMO domain. With certified facilities, a strong product mix, and decent financial performance, it provides early investors a chance to ride the company’s growth trajectory. That said, valuation risk and SME volatility should be considered.

• Opportunities: High-growth sector, early entry
• Risks: Volatility, valuation sensitivity, regulatory challenges